Nuveen LLC Makes New $3.81 Million Investment in Harmony Biosciences Holdings, Inc. $HRMY

Key Points

• Nuveen LLC has acquired 114,634 shares of Harmony Biosciences Holdings, valued at approximately $3.8 million, bringing their total ownership to 0.20% as of their latest SEC filing.
• Harmony Biosciences reported Q2 earnings of $0.68 per share, missing analysts' expectations, and its quarterly revenue of $200.49 million fell short of the forecasted $204.37 million.
• The stock price of Harmony Biosciences has increased by 2.4%, with recent analyst ratings indicating a consensus "Buy" rating and an average price target of $51.00.

Nuveen LLC purchased a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 114,634 shares of the company's stock, valued at approximately $3,805,000. Nuveen LLC owned approximately 0.20% of Harmony Biosciences at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Aurora Investment Counsel raised its holdings in Harmony Biosciences by 0.6% during the 1st quarter. Aurora Investment Counsel now owns 61,667 shares of the company's stock worth $2,047,000 after buying an additional 374 shares during the period. Rhumbline Advisers raised its holdings in Harmony Biosciences by 0.4% during the 1st quarter. Rhumbline Advisers now owns 109,073 shares of the company's stock worth $3,620,000 after buying an additional 485 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Harmony Biosciences by 1.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 62,331 shares of the company's stock worth $2,145,000 after buying an additional 678 shares during the period. BOKF NA raised its holdings in Harmony Biosciences by 4.7% during the 4th quarter. BOKF NA now owns 15,400 shares of the company's stock worth $521,000 after buying an additional 690 shares during the period. Finally, CWM LLC raised its holdings in Harmony Biosciences by 34.8% during the 1st quarter. CWM LLC now owns 2,704 shares of the company's stock worth $90,000 after buying an additional 698 shares during the period. 86.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

HRMY has been the topic of several recent analyst reports. Cantor Fitzgerald upgraded Harmony Biosciences to a "strong-buy" rating in a report on Tuesday, May 13th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $55.00 price target (up from $54.00) on shares of Harmony Biosciences in a research report on Thursday, July 10th. Mizuho increased their price target on shares of Harmony Biosciences from $44.00 to $48.00 and gave the stock an "outperform" rating in a research report on Thursday, May 15th. The Goldman Sachs Group initiated coverage on shares of Harmony Biosciences in a research report on Thursday, July 10th. They issued a "neutral" rating and a $33.00 price target for the company. Finally, Needham & Company LLC reissued a "buy" rating and issued a $49.00 price target on shares of Harmony Biosciences in a research report on Tuesday, May 6th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $51.00.

Harmony Biosciences Stock Up 0.6%

Shares of NASDAQ HRMY traded up $0.21 during trading hours on Tuesday, hitting $37.10. The stock had a trading volume of 816,263 shares, compared to its average volume of 476,642. The company has a market capitalization of $2.13 billion, a P/E ratio of 11.97, a P/E/G ratio of 0.43 and a beta of 0.84. The firm's 50-day moving average price is $35.18 and its two-hundred day moving average price is $33.61. Harmony Biosciences Holdings, Inc. has a 52 week low of $26.47 and a 52 week high of $41.61. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.80 and a current ratio of 3.84.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 EPS for the quarter, missing the consensus estimate of $0.78 by ($0.10). The firm had revenue of $200.49 million during the quarter, compared to the consensus estimate of $204.37 million. Harmony Biosciences had a net margin of 23.44% and a return on equity of 26.34%. The company's quarterly revenue was up 16.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.05 EPS. Harmony Biosciences has set its FY 2025 guidance at EPS. Analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.